BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, Bauer M, Stein C, Deshpande S, Wardell C, Buzder T, Molnar G, Zangari M, van Rhee F, Thanendrarajan S, Schinke C, Epstein J, Davies FE, Walker BA, Meissner T, Barlogie B, Morgan GJ, Weinhold N. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun. 2017;8:268. [PMID: 28814763 DOI: 10.1038/s41467-017-00296-y] [Cited by in Crossref: 142] [Cited by in F6Publishing: 134] [Article Influence: 35.5] [Reference Citation Analysis]
Number Citing Articles
1 Corre J, Cleynen A, Robiou du Pont S, Buisson L, Bolli N, Attal M, Munshi N, Avet-Loiseau H. Multiple myeloma clonal evolution in homogeneously treated patients. Leukemia 2018;32:2636-47. [PMID: 29895955 DOI: 10.1038/s41375-018-0153-6] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 15.0] [Reference Citation Analysis]
2 Furukawa Y, Kikuchi J. Molecular basis of clonal evolution in multiple myeloma. Int J Hematol 2020;111:496-511. [DOI: 10.1007/s12185-020-02829-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
3 Bertamini L, D'Agostino M, Gay F. MRD Assessment in Multiple Myeloma: Progress and Challenges. Curr Hematol Malig Rep 2021;16:162-71. [PMID: 33950462 DOI: 10.1007/s11899-021-00633-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ntanasis-Stathopoulos I, Gavriatopoulou M, Terpos E, Fotiou D, Kastritis E, Dimopoulos MA. Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis. Clin Lymphoma Myeloma Leuk 2020;20:e905-9. [PMID: 32723621 DOI: 10.1016/j.clml.2020.06.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Yasui H, Kobayashi M, Sato K, Kondoh K, Ishida T, Kaito Y, Tamura H, Handa H, Tsukune Y, Sasaki M, Komatsu N, Tanaka N, Tanaka J, Kizaki M, Kawamata T, Makiyama J, Yokoyama K, Imoto S, Tojo A, Imai Y. Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse. Int J Clin Oncol 2021. [PMID: 34259983 DOI: 10.1007/s10147-021-01991-z] [Reference Citation Analysis]
6 Waldschmidt JM, Anand P, Knoechel B, Lohr JG. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease. Semin Hematol 2018;55:33-7. [PMID: 29759150 DOI: 10.1053/j.seminhematol.2018.02.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
7 Kint N, Vlayen S, Delforge M. The treatment of multiple myeloma in an era of precision medicine. Expert Review of Precision Medicine and Drug Development 2019;4:153-62. [DOI: 10.1080/23808993.2019.1606672] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, Alonso A, Sperling AS, Campbell T, Petrocca F, Hege K, Kaiser S, Loiseau HA, Anderson KC, Munshi NC. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun 2021;12:868. [PMID: 33558511 DOI: 10.1038/s41467-021-21177-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 16.0] [Reference Citation Analysis]
9 Bai Y, Su X. Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma. Asia Pac J Clin Oncol 2021;17:29-35. [PMID: 32920949 DOI: 10.1111/ajco.13459] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Jacobs S, Ausema A, Zwart E, Weersing E, Kingma MJ, El Menshawi YAS, de Haan G, Bystrykh LV, Belderbos ME. Quantitative distribution of patient-derived leukemia clones in murine xenografts revealed by cellular barcodes. Leukemia 2020;34:1669-74. [PMID: 31852987 DOI: 10.1038/s41375-019-0695-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Bailly C, Bodet-Milin C, Bourgeois M, Gouard S, Ansquer C, Barbaud M, Sébille JC, Chérel M, Kraeber-Bodéré F, Carlier T. Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture. Cancers (Basel) 2019;11:E1282. [PMID: 31480470 DOI: 10.3390/cancers11091282] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
12 Mina R, Oliva S, Boccadoro M. Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives. J Clin Med 2020;9:E2142. [PMID: 32645952 DOI: 10.3390/jcm9072142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
13 Takakuwa T, Ohta K, Nakatani E, Ito T, Kaneko H, Fuchida SI, Shimura Y, Yagi H, Shibayama H, Kanda J, Uchiyama H, Kosugi S, Tanaka H, Kawata E, Uoshima N, Ishikawa J, Shibano M, Karasuno T, Shindo M, Shimizu Y, Imada K, Kanakura Y, Kuroda J, Hino M, Nomura S, Takaori-Kondo A, Shimazaki C, Matsumura I. Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma. Hematol Oncol 2021;39:349-57. [PMID: 33724498 DOI: 10.1002/hon.2863] [Reference Citation Analysis]
14 Maura F, Boyle EM, Rustad EH, Ashby C, Kaminetzky D, Bruno B, Braunstein M, Bauer M, Blaney P, Wang Y, Ghamlouch H, Williams L, Stoeckle J, Davies FE, Walker BA, Maclachlan K, Diamond B, Landgren O, Morgan GJ. Chromothripsis as a pathogenic driver of multiple myeloma. Semin Cell Dev Biol 2021:S1084-9521(21)00087-2. [PMID: 33958284 DOI: 10.1016/j.semcdb.2021.04.014] [Reference Citation Analysis]
15 Zamagni E, Tacchetti P, Barbato S, Cavo M. Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients. J Clin Med 2020;9:E3519. [PMID: 33142671 DOI: 10.3390/jcm9113519] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
16 Zeissig MN, Zannettino ACW, Vandyke K. Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma. Cancers (Basel) 2020;12:E3643. [PMID: 33291672 DOI: 10.3390/cancers12123643] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Berger N, Kim-Schulze S, Parekh S. Minimal Residual Disease in Multiple Myeloma: Impact on Response Assessment, Prognosis and Tumor Heterogeneity. Adv Exp Med Biol. 2018;1100:141-159. [PMID: 30411265 DOI: 10.1007/978-3-319-97746-1_9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
18 Yao Q, Morgan GJ, Chim CS. Distinct promoter methylation profile reveals spatial epigenetic heterogeneity in 2 myeloma patients with multifocal extramedullary relapses. Clin Epigenetics 2018;10:158. [PMID: 30572945 DOI: 10.1186/s13148-018-0597-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Baertsch MA, Lutz R, Raab MS, Weinhold N, Goldschmidt H. Meeting report of the 7th Heidelberg Myeloma Workshop: today and tomorrow. J Cancer Res Clin Oncol 2019;145:2445-55. [PMID: 31407112 DOI: 10.1007/s00432-019-02998-w] [Reference Citation Analysis]
20 Da Vià MC, Solimando AG, Garitano-Trojaola A, Barrio S, Munawar U, Strifler S, Haertle L, Rhodes N, Teufel E, Vogt C, Lapa C, Beilhack A, Rasche L, Einsele H, Kortüm KM. CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement. Oncologist 2020;25:112-8. [PMID: 32043788 DOI: 10.1634/theoncologist.2019-0356] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
21 Rasche L, Hudecek M, Einsele H. What is the future of immunotherapy in multiple myeloma? Blood 2020;136:2491-7. [PMID: 32735639 DOI: 10.1182/blood.2019004176] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
22 Sessa M, Cavazzini F, Cavallari M, Rigolin GM, Cuneo A. A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results. Genes (Basel) 2020;11:E1453. [PMID: 33287156 DOI: 10.3390/genes11121453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Kaddoura M, Dingli D, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Kapoor P, Hwa L, Fonder A, Hobbs M, Hayman S, Lust J, Leung N, Go RS, Lin Y, Gonsalves W, Kourelis T, Warsame R, Kyle RA, Broski SM, Rajkumar V, Kumar S. Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. Blood Adv 2021;5:2753-9. [PMID: 34242392 DOI: 10.1182/bloodadvances.2020004131] [Reference Citation Analysis]
24 Mithraprabhu S, Morley R, Khong T, Kalff A, Bergin K, Hocking J, Savvidou I, Bowen KM, Ramachandran M, Choi K, Wong BKL, Reynolds J, Spencer A. Monitoring tumour burden and therapeutic response through analysis of circulating tumour DNA and extracellular RNA in multiple myeloma patients. Leukemia 2019;33:2022-33. [PMID: 30992504 DOI: 10.1038/s41375-019-0469-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
25 Čepulytė R, Žučenka A, Pečeliūnas V. Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation. Case Rep Hematol 2020;2020:8894031. [PMID: 33123389 DOI: 10.1155/2020/8894031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Guo G, Raje NS, Seifer C, Kloeber J, Isenhart R, Ha G, Yee AJ, O'Donnell EK, Tai YT, Richardson PG, Bianchi G, Laubach JP, Warren D, Gemme E, Voisine J, Frede J, Kokkalis A, Yun H, Dimitrova V, Vijaykumar T, Meyerson M, Munshi NC, Anderson KC, Knoechel B, Lohr JG. Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia 2018;32:1838-41. [PMID: 29749395 DOI: 10.1038/s41375-018-0115-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
27 Alzrigat M, Jernberg-Wiklund H, Licht JD. Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor Activity. Epigenomes 2018;2:16. [PMID: 30761216 DOI: 10.3390/epigenomes2030016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
28 Mithraprabhu S, Spencer A. Liquid Biopsy in Multiple Myeloma. In: Guenova M, Balatzenko G, editors. Hematology - Latest Research and Clinical Advances. InTech; 2018. [DOI: 10.5772/intechopen.72652] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Tagliafico AS. Imaging in multiple myeloma: Computed tomography or magnetic resonance imaging? World J Radiol 2021; 13(7): 223-226 [PMID: 34367508 DOI: 10.4329/wjr.v13.i7.223] [Reference Citation Analysis]
30 Zamagni E, Nanni C, Dozza L, Carlier T, Bailly C, Tacchetti P, Versari A, Chauvie S, Gallamini A, Gamberi B, Caillot D, Patriarca F, Macro M, Boccadoro M, Garderet L, Barbato S, Fanti S, Perrot A, Gay F, Sonneveld P, Karlin L, Cavo M, Bodet-milin C, Moreau P, Kraeber-bodéré F. Standardization of 18 F-FDG–PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. JCO 2021;39:116-25. [DOI: 10.1200/jco.20.00386] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
31 Maura F, Bolli N, Angelopoulos N, Dawson KJ, Leongamornlert D, Martincorena I, Mitchell TJ, Fullam A, Gonzalez S, Szalat R, Abascal F, Rodriguez-Martin B, Samur MK, Glodzik D, Roncador M, Fulciniti M, Tai YT, Minvielle S, Magrangeas F, Moreau P, Corradini P, Anderson KC, Tubio JMC, Wedge DC, Gerstung M, Avet-Loiseau H, Munshi N, Campbell PJ. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat Commun 2019;10:3835. [PMID: 31444325 DOI: 10.1038/s41467-019-11680-1] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 34.5] [Reference Citation Analysis]
32 Capp JP, Bataille R. Multiple Myeloma Exemplifies a Model of Cancer Based on Tissue Disruption as the Initiator Event. Front Oncol 2018;8:355. [PMID: 30250824 DOI: 10.3389/fonc.2018.00355] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
33 Corre J, Avet-Loiseau H. Risk-Based Therapeutic Strategies. Cancer J 2019;25:54-8. [PMID: 30694860 DOI: 10.1097/PPO.0000000000000352] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
34 Bhutani M, Foureau DM, Atrash S, Voorhees PM, Usmani SZ. Extramedullary multiple myeloma. Leukemia 2020;34:1-20. [DOI: 10.1038/s41375-019-0660-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 17.5] [Reference Citation Analysis]
35 Mithraprabhu S, Sirdesai S, Chen M, Khong T, Spencer A. Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma. Int J Mol Sci 2018;19:E1858. [PMID: 29937522 DOI: 10.3390/ijms19071858] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
36 Garcés JJ, Bretones G, Burgos L, Valdes-Mas R, Puig N, Cedena MT, Alignani D, Rodriguez I, Puente DÁ, Álvarez MG, Goicoechea I, Rodriguez S, Calasanz MJ, Agirre X, Flores-Montero J, Sanoja-Flores L, Rodriguez-Otero P, Rios R, Martinez-Lopez J, Millacoy P, Palomera L, Del Orbe R, Pérez-Montaña A, El Omri H, Prosper F, Mateos MV, Rosiñol L, Blade J, Lahuerta JJ, Orfao A, Lopez-Otin C, San Miguel JF, Paiva B; GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group. Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma. Leukemia 2020;34:3007-18. [PMID: 32475991 DOI: 10.1038/s41375-020-0883-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Bailly C, Carlier T, Jamet B, Touzeau C, Moreau P, Kraeber-Bodéré F, Bodet-Milin C. 18F-FDG PET/CT in multiple myeloma: critical insights and future directions. Eur J Nucl Med Mol Imaging 2019;46:1048-50. [PMID: 30770949 DOI: 10.1007/s00259-019-04279-7] [Reference Citation Analysis]
38 Sun Y, Xu Z, Jiang J, Xu T, Xu J, Liu P. High Expression of Succinate Dehydrogenase Subunit A Which Is Regulated by Histone Acetylation, Acts as a Good Prognostic Factor of Multiple Myeloma Patients. Front Oncol 2020;10:563666. [PMID: 33014881 DOI: 10.3389/fonc.2020.563666] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Uckun FM, Qazi S, Demirer T, Champlin RE. Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma. EBioMedicine 2019;39:612-20. [PMID: 30545798 DOI: 10.1016/j.ebiom.2018.12.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
40 Pawlyn C, Davies FE. Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood 2019;133:660-75. [PMID: 30587529 DOI: 10.1182/blood-2018-09-825331] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 15.3] [Reference Citation Analysis]
41 Dutta AK, Fink JL, Grady JP, Morgan GJ, Mullighan CG, To LB, Hewett DR, Zannettino ACW. Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability. Leukemia 2019;33:457-68. [PMID: 30046162 DOI: 10.1038/s41375-018-0206-x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 15.3] [Reference Citation Analysis]
42 Ainscough BJ, Barnell EK, Ronning P, Campbell KM, Wagner AH, Fehniger TA, Dunn GP, Uppaluri R, Govindan R, Rohan TE, Griffith M, Mardis ER, Swamidass SJ, Griffith OL. A deep learning approach to automate refinement of somatic variant calling from cancer sequencing data. Nat Genet 2018;50:1735-43. [PMID: 30397337 DOI: 10.1038/s41588-018-0257-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 9.7] [Reference Citation Analysis]
43 Barbato A, Scandura G, Puglisi F, Cambria D, La Spina E, Palumbo GA, Lazzarino G, Tibullo D, Di Raimondo F, Giallongo C, Romano A. Mitochondrial Bioenergetics at the Onset of Drug Resistance in Hematological Malignancies: An Overview. Front Oncol 2020;10:604143. [PMID: 33409153 DOI: 10.3389/fonc.2020.604143] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
44 Vandyke K. Seed and soil revisited in multiple myeloma. Blood 2021;137:2282-3. [PMID: 33914079 DOI: 10.1182/blood.2020009555] [Reference Citation Analysis]
45 [DOI: 10.1101/388611] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Belotti A, Ribolla R, Cancelli V, Villanacci A, Angelini V, Chiarini M, Giustini V, Facchetti GV, Roccaro AM, Ferrari S, Peli A, Bottelli C, Cattaneo C, Crippa C, Micilotta M, Frittoli B, Grazioli L, Rossi G, Tucci A. Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry. Cancer Med 2021;10:5859-65. [PMID: 34263564 DOI: 10.1002/cam4.4136] [Reference Citation Analysis]
47 Richter J, Jagannath S. Society of Hematologic Oncology State of the Art Update and Next Questions: Multiple Myeloma. Clin Lymphoma Myeloma Leuk 2018;18:693-702. [PMID: 30287199 DOI: 10.1016/j.clml.2018.09.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Bal S, Weaver A, Cornell RF, Costa LJ. Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma. Br J Haematol 2019;186:807-19. [PMID: 31364160 DOI: 10.1111/bjh.16130] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
49 Fitzpatrick MJ, Nardi V, Sohani AR. Plasma cell myeloma: role of histopathology, immunophenotyping, and genetic testing. Skeletal Radiol 2021. [PMID: 33687521 DOI: 10.1007/s00256-021-03754-3] [Reference Citation Analysis]
50 Ferreira B, Caetano J, Barahona F, Lopes R, Carneiro E, Costa-Silva B, João C. Liquid biopsies for multiple myeloma in a time of precision medicine. J Mol Med (Berl) 2020;98:513-25. [PMID: 32246161 DOI: 10.1007/s00109-020-01897-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
51 Gambella M, Omedé P, Spada S, Muccio VE, Gilestro M, Saraci E, Grammatico S, Larocca A, Conticello C, Bernardini A, Gamberi B, Troia R, Liberati AM, Offidani M, Rocci A, Palumbo A, Cavo M, Sonneveld P, Boccadoro M, Oliva S. Minimal residual disease by flow cytometry and allelic‐specific oligonucleotide real‐time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis. Cancer 2019;125:750-60. [DOI: 10.1002/cncr.31854] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
52 Rasche L, Kortüm KM, Raab MS, Weinhold N. The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma. Int J Mol Sci 2019;20:E1248. [PMID: 30871078 DOI: 10.3390/ijms20051248] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 13.0] [Reference Citation Analysis]
53 Mogollón P, Díaz-Tejedor A, Algarín EM, Paíno T, Garayoa M, Ocio EM. Biological Background of Resistance to Current Standards of Care in Multiple Myeloma. Cells 2019;8:E1432. [PMID: 31766279 DOI: 10.3390/cells8111432] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
54 Silva Y, Riedinger JM, Chrétien ML, Caillot D, Corre J, Guillen K, Cochet A, Tabouret-Viaud C, Loffroy R. Comparison between tumour metabolism derived from 18F-FDG PET/CT and accurate cytogenetic stratification in newly diagnosed multiple myeloma patients. Quant Imaging Med Surg 2021;11:4299-309. [PMID: 34603985 DOI: 10.21037/qims-21-85] [Reference Citation Analysis]
55 Schavgoulidze A, Cazaubiel T, Perrot A, Avet-Loiseau H, Corre J. Multiple Myeloma: Heterogeneous in Every Way. Cancers (Basel) 2021;13:1285. [PMID: 33805803 DOI: 10.3390/cancers13061285] [Reference Citation Analysis]
56 Ledergor G, Weiner A, Zada M, Wang S, Cohen YC, Gatt ME, Snir N, Magen H, Koren-michowitz M, Herzog-tzarfati K, Keren-shaul H, Bornstein C, Rotkopf R, Yofe I, David E, Yellapantula V, Kay S, Salai M, Ben Yehuda D, Nagler A, Shvidel L, Orr-urtreger A, Halpern KB, Itzkovitz S, Landgren O, San-miguel J, Paiva B, Keats JJ, Papaemmanuil E, Avivi I, Barbash GI, Tanay A, Amit I. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. Nat Med 2018;24:1867-76. [DOI: 10.1038/s41591-018-0269-2] [Cited by in Crossref: 80] [Cited by in F6Publishing: 72] [Article Influence: 26.7] [Reference Citation Analysis]
57 Manzoni M, Pompa A, Fabris S, Pelizzoni F, Ciceri G, Seia M, Ziccheddu B, Bolli N, Corradini P, Baldini L, Neri A, Lionetti M. Limits and Applications of Genomic Analysis of Circulating Tumor DNA as a Liquid Biopsy in Asymptomatic Forms of Multiple Myeloma. Hemasphere 2020;4:e402. [PMID: 32903996 DOI: 10.1097/HS9.0000000000000402] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
58 Jones JR, Weinhold N, Ashby C, Walker BA, Wardell C, Pawlyn C, Rasche L, Melchor L, Cairns DA, Gregory WM, Johnson D, Begum DB, Ellis S, Sherborne AL, Cook G, Kaiser MF, Drayson MT, Owen RG, Jackson GH, Davies FE, Greaves M, Morgan GJ; NCRI Haemato-Oncology CSG. Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. Haematologica 2019;104:1440-50. [PMID: 30733268 DOI: 10.3324/haematol.2018.202200] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
59 Jamet B, Zamagni E, Nanni C, Bailly C, Carlier T, Touzeau C, Michaud AV, Moreau P, Bodet-Milin C, Kraeber-Bodere F. Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma. Int J Mol Sci 2020;21:E5406. [PMID: 32751375 DOI: 10.3390/ijms21155406] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
60 Morgan GJ, He J, Tytarenko R, Patel P, Stephens OW, Zhong S, Deshpande S, Bauer M, Weinhold N, Schinke C, Rasche L, Bailey M, Ali S, Ross J, Miller VA, Stephens P, Thanendrarajan S, Zangari M, van Rhee F, Mughal T, Davies FE, Walker BA. Kinase domain activation through gene rearrangement in multiple myeloma. Leukemia 2018;32:2435-44. [PMID: 29654269 DOI: 10.1038/s41375-018-0108-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
61 Patel UH, Drabick JJ, Malysz J, Talamo G. Nonsecretory and Light Chain Escape in Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk 2018;18:e515-9. [PMID: 30201257 DOI: 10.1016/j.clml.2018.06.028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
62 Da Vià MC, Dietrich O, Truger M, Arampatzi P, Duell J, Heidemeier A, Zhou X, Danhof S, Kraus S, Chatterjee M, Meggendorfer M, Twardziok S, Goebeler ME, Topp MS, Hudecek M, Prommersberger S, Hege K, Kaiser S, Fuhr V, Weinhold N, Rosenwald A, Erhard F, Haferlach C, Einsele H, Kortüm KM, Saliba AE, Rasche L. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med 2021;27:616-9. [PMID: 33619368 DOI: 10.1038/s41591-021-01245-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
63 Morgan GJ, Boyle EM, Davies FE. From Bench to Bedside: The Evolution of Genomics and Its Implications for the Current and Future Management of Multiple Myeloma. Cancer J 2021;27:213-21. [PMID: 34549910 DOI: 10.1097/PPO.0000000000000523] [Reference Citation Analysis]
64 Ames J, Al-Samaraee A, Takahashi T. Extraosseous Multiple Myeloma: Case Report of Presentation in the Lower Extremity Soft Tissues with Literature Review. Case Rep Radiol 2017;2017:9159035. [PMID: 29391963 DOI: 10.1155/2017/9159035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
65 Tachita T, Kinoshita S, Ri M, Aoki S, Asano A, Kanamori T, Yoshida T, Totani H, Ito A, Kusumoto S, Komatsu H, Yamagata K, Kubo K, Tohkin M, Fukuda S, Iida S. Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma. Cancer Sci 2020;111:1333-43. [PMID: 32061138 DOI: 10.1111/cas.14352] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
66 Jöhrer K, Ҫiҫek SS. Multiple Myeloma Inhibitory Activity of Plant Natural Products. Cancers (Basel) 2021;13:2678. [PMID: 34072312 DOI: 10.3390/cancers13112678] [Reference Citation Analysis]
67 Messiou C, Porta N, Sharma B, Levine D, Koh DM, Boyd K, Pawlyn C, Riddell A, Downey K, Croft J, Morgan V, Stern S, Cheung B, Kyriakou C, Kaczmarek P, Winfield J, Blackledge M, Oyen WJG, Kaiser MF. Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma. Radiol Imaging Cancer 2021;3:e210048. [PMID: 34559006 DOI: 10.1148/rycan.2021210048] [Reference Citation Analysis]
68 John L, Krauth MT, Podar K, Raab MS. Pathway-Directed Therapy in Multiple Myeloma. Cancers (Basel) 2021;13:1668. [PMID: 33916289 DOI: 10.3390/cancers13071668] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Bolli N, Genuardi E, Ziccheddu B, Martello M, Oliva S, Terragna C. Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time? Front Oncol 2020;10:189. [PMID: 32181154 DOI: 10.3389/fonc.2020.00189] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
70 Latifoltojar A, Boyd K, Riddell A, Kaiser M, Messiou C. Characterising spatial heterogeneity of multiple myeloma in high resolution by whole body magnetic resonance imaging: Towards macro-phenotype driven patient management. Magn Reson Imaging 2021;75:60-4. [PMID: 33075451 DOI: 10.1016/j.mri.2020.10.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Waldschmidt JM, Vijaykumar T, Knoechel B, Lohr JG. Tracking myeloma tumor DNA in peripheral blood. Best Pract Res Clin Haematol 2020;33:101146. [PMID: 32139012 DOI: 10.1016/j.beha.2020.101146] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Rasche L, Weinhold N. Pathogenese des Multiplen Myeloms. Internist 2019;60:3-9. [DOI: 10.1007/s00108-018-0529-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
73 Farre L, Sanz G, Ruiz-Xivillé N, Castro de Moura M, Martin-Tejera JF, Gonçalves-Ribeiro S, Martinez-Iniesta M, Calaf M, Luis Mosquera J, Martín-Subero JI, Granada I, Esteller M, Domingo-Domenech E, Climent F, Villanueva A, Sureda A. Extramedullary multiple myeloma patient-derived orthotopic xenograft with a highly altered genome: combined molecular and therapeutic studies. Dis Model Mech 2021;14:dmm048223. [PMID: 33988237 DOI: 10.1242/dmm.048223] [Reference Citation Analysis]
74 Wennmann M, Hielscher T, Kintzelé L, Menze BH, Langs G, Merz M, Sauer S, Kauczor HU, Schlemmer HP, Delorme S, Goldschmidt H, Weinhold N, Hillengass J, Weber MA. Analyzing Longitudinal wb-MRI Data and Clinical Course in a Cohort of Former Smoldering Multiple Myeloma Patients: Connections between MRI Findings and Clinical Progression Patterns. Cancers (Basel) 2021;13:961. [PMID: 33668879 DOI: 10.3390/cancers13050961] [Reference Citation Analysis]
75 Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos M, Lonial S, Joao C, Anderson KC, García-sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen W, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. The Lancet Oncology 2019;20:e302-12. [DOI: 10.1016/s1470-2045(19)30309-2] [Cited by in Crossref: 113] [Cited by in F6Publishing: 53] [Article Influence: 56.5] [Reference Citation Analysis]
76 Mithraprabhu S, Chen M, Savvidou I, Reale A, Spencer A. Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disorders. Leukemia 2021. [PMID: 34262132 DOI: 10.1038/s41375-021-01339-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
77 Romano A, Cerchione C, Conticello C, Martinelli G, Di Raimondo F. How we manage smoldering multiple myeloma. Hematol Rep 2020;12:8951. [PMID: 33042502 DOI: 10.4081/hr.2020.8951] [Reference Citation Analysis]
78 Jamet B, Bailly C, Carlier T, Touzeau C, Nanni C, Zamagni E, Barré L, Michaud AV, Chérel M, Moreau P, Bodet-Milin C, Kraeber-Bodéré F. Interest of Pet Imaging in Multiple Myeloma. Front Med (Lausanne) 2019;6:69. [PMID: 31024917 DOI: 10.3389/fmed.2019.00069] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
79 Bolli N, Martinelli G, Cerchione C. The molecular pathogenesis of multiple myeloma. Hematol Rep 2020;12:9054. [PMID: 33408844 DOI: 10.4081/hr.2020.9054] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Kriegova E, Fillerova R, Minarik J, Savara J, Manakova J, Petrackova A, Dihel M, Balcarkova J, Krhovska P, Pika T, Gajdos P, Behalek M, Vasinek M, Papajik T. Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities. Sci Rep 2021;11:14671. [PMID: 34282158 DOI: 10.1038/s41598-021-93835-z] [Reference Citation Analysis]
81 Salomon-Perzyński A, Jamroziak K, Głodkowska-Mrówka E. Clonal Evolution of Multiple Myeloma-Clinical and Diagnostic Implications. Diagnostics (Basel) 2021;11:1534. [PMID: 34573876 DOI: 10.3390/diagnostics11091534] [Reference Citation Analysis]
82 Wennmann M, Kintzelé L, Piraud M, Menze BH, Hielscher T, Hofmanninger J, Wagner B, Kauczor HU, Merz M, Hillengass J, Langs G, Weber MA. Volumetry based biomarker speed of growth: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients. Oncotarget 2018;9:25254-64. [PMID: 29861868 DOI: 10.18632/oncotarget.25402] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
83 Hemminki K, Försti A, Houlston R, Sud A. Epidemiology, genetics and treatment of multiple myeloma and precursor diseases. Int J Cancer 2021. [PMID: 34398972 DOI: 10.1002/ijc.33762] [Reference Citation Analysis]
84 Stephens OW, Meißner T, Weinhold N. Detection of Cross-Sample Contamination in Multiple Myeloma Samples and Sequencing Data. Methods Mol Biol 2018;1792:147-55. [PMID: 29797257 DOI: 10.1007/978-1-4939-7865-6_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
85 van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet 2021;397:410-27. [PMID: 33516340 DOI: 10.1016/S0140-6736(21)00135-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 25.0] [Reference Citation Analysis]
86 Aktas Samur A, Minvielle S, Shammas M, Fulciniti M, Magrangeas F, Richardson PG, Moreau P, Attal M, Anderson KC, Parmigiani G, Avet-Loiseau H, Munshi NC, Samur MK. Deciphering the chronology of copy number alterations in Multiple Myeloma. Blood Cancer J 2019;9:39. [PMID: 30914633 DOI: 10.1038/s41408-019-0199-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
87 Ghose J, Viola D, Terrazas C, Caserta E, Troadec E, Khalife J, Gunes EG, Sanchez J, McDonald T, Marcucci G, Kaur B, Rosenzweig M, Keats J, Rosen S, Krishnan A, Satoskar AR, Hofmeister CC, Pichiorri F. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology 2018;7:e1486948. [PMID: 30288349 DOI: 10.1080/2162402X.2018.1486948] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 7.7] [Reference Citation Analysis]
88 Giuliani N, Malavasi F. Editorial: Immunotherapy in Multiple Myeloma. Front Immunol 2019;10:1945. [PMID: 31475006 DOI: 10.3389/fimmu.2019.01945] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
89 Zhou X, Flüchter P, Nickel K, Meckel K, Messerschmidt J, Böckle D, Knorz S, Steinhardt MJ, Krummenast F, Danhof S, Einsele H, Kortüm KM, Rasche L. Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease. Cancers (Basel) 2020;12:E1035. [PMID: 32340174 DOI: 10.3390/cancers12041035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
90 Opasic L, Zhou D, Werner B, Dingli D, Traulsen A. How many samples are needed to infer truly clonal mutations from heterogenous tumours? BMC Cancer 2019;19:403. [PMID: 31035962 DOI: 10.1186/s12885-019-5597-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
91 Akhmetzyanova I, McCarron MJ, Parekh S, Chesi M, Bergsagel PL, Fooksman DR. Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination. Leukemia 2020;34:245-56. [PMID: 31439945 DOI: 10.1038/s41375-019-0519-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
92 Barnell EK, Ronning P, Campbell KM, Krysiak K, Ainscough BJ, Sheta LM, Pema SP, Schmidt AD, Richters M, Cotto KC, Danos AM, Ramirez C, Skidmore ZL, Spies NC, Hundal J, Sediqzad MS, Kunisaki J, Gomez F, Trani L, Matlock M, Wagner AH, Swamidass SJ, Griffith M, Griffith OL. Standard operating procedure for somatic variant refinement of sequencing data with paired tumor and normal samples. Genet Med 2019;21:972-81. [PMID: 30287923 DOI: 10.1038/s41436-018-0278-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 10.7] [Reference Citation Analysis]
93 Kostopoulos IV, Ntanasis-Stathopoulos I, Gavriatopoulou M, Tsitsilonis OE, Terpos E. Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches. Front Oncol 2020;10:860. [PMID: 32537439 DOI: 10.3389/fonc.2020.00860] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
94 Rustad EH, Yellapantula V, Leongamornlert D, Bolli N, Ledergor G, Nadeu F, Angelopoulos N, Dawson KJ, Mitchell TJ, Osborne RJ, Ziccheddu B, Carniti C, Montefusco V, Corradini P, Anderson KC, Moreau P, Papaemmanuil E, Alexandrov LB, Puente XS, Campo E, Siebert R, Avet-Loiseau H, Landgren O, Munshi N, Campbell PJ, Maura F. Timing the initiation of multiple myeloma. Nat Commun 2020;11:1917. [PMID: 32317634 DOI: 10.1038/s41467-020-15740-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 34.0] [Reference Citation Analysis]
95 Boyle EM, Deshpande S, Tytarenko R, Ashby C, Wang Y, Bauer MA, Johnson SK, Wardell CP, Thanendrarajan S, Zangari M, Facon T, Dumontet C, Barlogie B, Arbini A, Rustad EH, Maura F, Landgren O, Zhan F, van Rhee F, Schinke C, Davies FE, Morgan GJ, Walker BA. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Nat Commun 2021;12:293. [PMID: 33436579 DOI: 10.1038/s41467-020-20524-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
96 Harding T, Baughn L, Kumar S, Van Ness B. The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies. Leukemia 2019;33:863-83. [PMID: 30683909 DOI: 10.1038/s41375-018-0362-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
97 Vlummens P, De Veirman K, Menu E, De Bruyne E, Offner F, Vanderkerken K, Maes K. The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma. Front Genet 2019;10:740. [PMID: 31475039 DOI: 10.3389/fgene.2019.00740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
98 Capp JP, Bataille R. Multiple Myeloma as a Bone Disease? The Tissue Disruption-Induced Cell Stochasticity (TiDiS) Theory. Cancers (Basel) 2020;12:E2158. [PMID: 32759688 DOI: 10.3390/cancers12082158] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
99 Kircher S, Stolzenburg A, Kortüm KM, Kircher M, Da Via M, Samnick S, Buck AK, Einsele H, Rosenwald A, Lapa C. Hexokinase-2 Expression in 11 C-Methionine–Positive, 18 F-FDG–Negative Multiple Myeloma. J Nucl Med 2019;60:348-52. [DOI: 10.2967/jnumed.118.217539] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
100 Holstein SA, Ye JC, Howard A, Bhutani M, Gormley N, Hahn T, Hillengass J, Krishnan A, Landgren CO, Munshi NC, Oliva S, Owen RG, Pasquini MC, Puig N, Weinhold N, Weisel K, McCarthy PL. Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biol Blood Marrow Transplant 2019;25:e89-97. [PMID: 30408566 DOI: 10.1016/j.bbmt.2018.11.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
101 Rasche L, Angtuaco EJ, Alpe TL, Gershner GH, McDonald JE, Samant RS, Kumar M, Van Hemert R, Epstein J, Deshpande S, Tytarenko R, Yaccoby S, Hillengass J, Thanendrarajan S, Schinke C, van Rhee F, Zangari M, Walker BA, Barlogie B, Morgan GJ, Davies FE, Weinhold N. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood 2018;132:59-66. [PMID: 29784643 DOI: 10.1182/blood-2018-04-842880] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 10.0] [Reference Citation Analysis]
102 Mithraprabhu S, Hocking J, Ramachandran M, Choi K, Klarica D, Khong T, Reynolds J, Spencer A. DNA-Repair Gene Mutations Are Highly Prevalent in Circulating Tumour DNA from Multiple Myeloma Patients. Cancers (Basel) 2019;11:E917. [PMID: 31261969 DOI: 10.3390/cancers11070917] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
103 Zamagni E, Tacchetti P, Cavo M. Imaging in multiple myeloma: How? When? Blood 2019;133:644-51. [PMID: 30587527 DOI: 10.1182/blood-2018-08-825356] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
104 Terao T, Machida Y, Hirata K, Kuzume A, Tabata R, Tsushima T, Miura D, Narita K, Takeuchi M, Tateishi U, Matsue K. Prognostic Impact of Metabolic Heterogeneity in Patients With Newly Diagnosed Multiple Myeloma Using 18F-FDG PET/CT. Clin Nucl Med 2021;46:790-6. [PMID: 34172600 DOI: 10.1097/RLU.0000000000003773] [Reference Citation Analysis]
105 Lutz R, Friedrich M, Raab MS, Weinhold N, Goldschmidt H. Therapeutic Advances Propelled by Deciphering Tumor Biology and Immunology-Highlights of the 8th Heidelberg Myeloma Workshop. Cancers (Basel) 2021;13:4135. [PMID: 34439297 DOI: 10.3390/cancers13164135] [Reference Citation Analysis]
106 Terao T, Machida Y, Narita K, Kuzume A, Tabata R, Tsushima T, Miura D, Takeuchi M, Tateishi U, Matsue K. Total diffusion volume in MRI vs. total lesion glycolysis in PET/CT for tumor volume evaluation of multiple myeloma. Eur Radiol 2021;31:6136-44. [PMID: 33496828 DOI: 10.1007/s00330-021-07687-2] [Reference Citation Analysis]
107 Kumar SK, Rajkumar SV. The multiple myelomas — current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol 2018;15:409-21. [DOI: 10.1038/s41571-018-0018-y] [Cited by in Crossref: 98] [Cited by in F6Publishing: 100] [Article Influence: 32.7] [Reference Citation Analysis]
108 Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell RF, Holstein SA, Shi Q, Omel J, Callander NS, Chng WJ, Hungria V, Maiolino A, Stadtmauer E, Giralt S, Pasquini M, Jakubowiak AJ, Morgan GJ, Krishnan A, Jackson GH, Mohty M, Mateos MV, Dimopoulos MA, Facon T, Spencer A, Miguel JS, Hari P, Usmani SZ, Manier S, Mccarthy P, Kumar S, Gay F, Paiva B. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia 2021;35:18-30. [DOI: 10.1038/s41375-020-01012-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
109 Hillengass J, Merz M, Delorme S. Minimal residual disease in multiple myeloma: use of magnetic resonance imaging. Semin Hematol 2018;55:19-21. [PMID: 29759148 DOI: 10.1053/j.seminhematol.2018.02.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
110 Morgan GJ, Rasche L. Maintaining therapeutic progress in multiple myeloma by integrating genetic and biological advances into the clinic. Expert Rev Hematol 2018;11:513-23. [PMID: 29944024 DOI: 10.1080/17474086.2018.1489718] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
111 Suzuki K, Nishiwaki K, Yano S. Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma. Cancers (Basel) 2021;13:E215. [PMID: 33435539 DOI: 10.3390/cancers13020215] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
112 Alonso R, Cedena MT, Gómez-Grande A, Ríos R, Moraleda JM, Cabañas V, Moreno MJ, López-Jiménez J, Martín F, Sanz A, Valeri A, Jiménez A, Sánchez R, Lahuerta JJ, Martínez-López J. Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma. Am J Hematol 2019;94:853-61. [PMID: 31074033 DOI: 10.1002/ajh.25507] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
113 Bochtler T, Merz M, Hielscher T, Granzow M, Hoffmann K, Krämer A, Raab MS, Hillengass J, Seckinger A, Kimmich C, Dittrich T, Müller-Tidow C, Hose D, Goldschmidt H, Hegenbart U, Jauch A, Schönland SO. Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. Blood Adv 2018;2:2607-18. [PMID: 30327369 DOI: 10.1182/bloodadvances.2018023200] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
114 Wang Y, An G, Qiu LG. [Progress in clonal evolution of multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi 2021;42:611-5. [PMID: 34455753 DOI: 10.3760/cma.j.issn.0253-2727.2021.07.017] [Reference Citation Analysis]
115 Gerber B, Manzoni M, Spina V, Bruscaggin A, Lionetti M, Fabris S, Barbieri M, Ciceri G, Pompa A, Forestieri G, Lerch E, Servida P, Bertoni F, Zucca E, Ghielmini M, Cortelezzi A, Cavalli F, Stussi G, Baldini L, Rossi D, Neri A. Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias. Haematologica 2018;103:e245-8. [PMID: 29472358 DOI: 10.3324/haematol.2017.184358] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
116 Bailly C, Chalopin B, Gouard S, Carlier T, Saëc PR, Marionneau-Lambot S, Moreau P, Touzeau C, Kraeber-Bodere F, Bodet-Milin C, Chérel M. ImmunoPET in Multiple Myeloma-What? So What? Now What? Cancers (Basel) 2020;12:E1467. [PMID: 32512883 DOI: 10.3390/cancers12061467] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
117 Ziccheddu B, Biancon G, Bagnoli F, De Philippis C, Maura F, Rustad EH, Dugo M, Devecchi A, De Cecco L, Sensi M, Terragna C, Martello M, Bagratuni T, Kastritis E, Dimopoulos MA, Cavo M, Carniti C, Montefusco V, Corradini P, Bolli N. Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. Blood Adv 2020;4:830-44. [PMID: 32126144 DOI: 10.1182/bloodadvances.2019000779] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 16.0] [Reference Citation Analysis]
118 Solimando AG, Da Vià MC, Cicco S, Leone P, Di Lernia G, Giannico D, Desantis V, Frassanito MA, Morizio A, Delgado Tascon J, Melaccio A, Saltarella I, Ranieri G, Ria R, Rasche L, Kortüm KM, Beilhack A, Racanelli V, Vacca A, Einsele H. High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment. J Clin Med 2019;8:E997. [PMID: 31323969 DOI: 10.3390/jcm8070997] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
119 Michaud-Robert AV, Jamet B, Bailly C, Carlier T, Moreau P, Touzeau C, Bourgeois M, Kraeber-Bodere F, Bodet-Milin C. FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients? Cancers (Basel) 2020;12:E1384. [PMID: 32481533 DOI: 10.3390/cancers12061384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Rengifo LY, Smits S, Buedts L, Delforge M, Dehaspe L, Tousseyn T, Boeckx N, Lehnert S, Michaux L, Vermeesch JR, Vandenberghe P, Dewaele B. Ultra-low coverage whole genome sequencing of ccfDNA in multiple myeloma: A tool for laboratory routine? Cancer Treat Res Commun 2021;28:100380. [PMID: 33962213 DOI: 10.1016/j.ctarc.2021.100380] [Reference Citation Analysis]
121 Dogliotti I, Drandi D, Genuardi E, Ferrero S. New Molecular Technologies for Minimal Residual Disease Evaluation in B-Cell Lymphoid Malignancies. J Clin Med 2018;7:E288. [PMID: 30231510 DOI: 10.3390/jcm7090288] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
122 Da Vià MC, Ziccheddu B, Maeda A, Bagnoli F, Perrone G, Bolli N. A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity. Hemasphere 2020;4:e502. [PMID: 33283171 DOI: 10.1097/HS9.0000000000000502] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
123 Rasche L, Alapat D, Kumar M, Gershner G, McDonald J, Wardell CP, Samant R, Van Hemert R, Epstein J, Williams AF, Thanendrarajan S, Schinke C, Bauer M, Ashby C, Tytarenko RG, van Rhee F, Walker BA, Zangari M, Barlogie B, Davies FE, Morgan GJ, Weinhold N. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia 2019;33:1713-22. [PMID: 30573775 DOI: 10.1038/s41375-018-0329-0] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 17.7] [Reference Citation Analysis]
124 Landau HJ, Yellapantula V, Diamond BT, Rustad EH, Maclachlan KH, Gundem G, Medina-Martinez J, Ossa JA, Levine MF, Zhou Y, Kappagantula R, Baez P, Attiyeh M, Makohon-Moore A, Zhang L, Boyle EM, Ashby C, Blaney P, Patel M, Zhang Y, Dogan A, Chung DJ, Giralt S, Lahoud OB, Peled JU, Scordo M, Shah G, Hassoun H, Korde NS, Lesokhin AM, Lu S, Mailankody S, Shah U, Smith E, Hultcrantz ML, Ulaner GA, van Rhee F, Morgan GJ, Landgren O, Papaemmanuil E, Iacobuzio-Donahue C, Maura F. Accelerated single cell seeding in relapsed multiple myeloma. Nat Commun 2020;11:3617. [PMID: 32680998 DOI: 10.1038/s41467-020-17459-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
125 Fernando RC, de Carvalho F, Leme AFP, Colleoni GWB. Tumor Microenvironment Proteomics: Lessons From Multiple Myeloma. Front Oncol 2021;11:563384. [PMID: 33833982 DOI: 10.3389/fonc.2021.563384] [Reference Citation Analysis]
126 Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan G. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia 2019;33:159-70. [PMID: 29967379 DOI: 10.1038/s41375-018-0196-8] [Cited by in Crossref: 141] [Cited by in F6Publishing: 139] [Article Influence: 47.0] [Reference Citation Analysis]
127 Wang C, Yang J, Luo H, Wang K, Wang Y, Xiao ZX, Tao X, Jiang H, Cai H. CancerTracer: a curated database for intrapatient tumor heterogeneity. Nucleic Acids Res 2020;48:D797-806. [PMID: 31701131 DOI: 10.1093/nar/gkz1061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
128 Davis LN, Sherbenou DW. Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma. Cancers (Basel) 2021;13:1686. [PMID: 33918370 DOI: 10.3390/cancers13071686] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
129 Richter J, Ramasamy K, Rasche L, Bladé J, Zweegman S, Davies F, Dimopoulos M. Management of patients with difficult-to-treat multiple myeloma. Future Oncol 2021;17:2089-105. [PMID: 33706558 DOI: 10.2217/fon-2020-1280] [Reference Citation Analysis]
130 Schürch CM, Rasche L, Frauenfeld L, Weinhold N, Fend F. A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration. Virchows Arch 2020;476:337-51. [PMID: 31848687 DOI: 10.1007/s00428-019-02725-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
131 Wu F, Bernard S, Fayad LM, Ilaslan H, Messiou C, Moulopoulos LA, Mulligan ME. Updates and Ongoing Challenges in Imaging of Multiple Myeloma: AJR Expert Panel Narrative Review. AJR Am J Roentgenol 2021;217:775-85. [PMID: 33978464 DOI: 10.2214/AJR.21.25878] [Reference Citation Analysis]
132 Maura F, Bolli N, Rustad EH, Hultcrantz M, Munshi N, Landgren O. Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review. JAMA Oncol 2020;6:425-32. [PMID: 31830214 DOI: 10.1001/jamaoncol.2019.4659] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 22.0] [Reference Citation Analysis]
133 Sinha VC, Piwnica-Worms H. Intratumoral Heterogeneity in Ductal Carcinoma In Situ: Chaos and Consequence. J Mammary Gland Biol Neoplasia 2018;23:191-205. [PMID: 30194658 DOI: 10.1007/s10911-018-9410-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
134 Zhou X, Dierks A, Kertels O, Samnick S, Kircher M, Buck AK, Haertle L, Knorz S, Böckle D, Scheller L, Messerschmidt J, Barakat M, Truger M, Haferlach C, Einsele H, Rasche L, Kortüm KM, Lapa C. The Link between Cytogenetics/Genomics and Imaging Patterns of Relapse and Progression in Patients with Relapsed/Refractory Multiple Myeloma: A Pilot Study Utilizing 18F-FDG PET/CT. Cancers (Basel) 2020;12:E2399. [PMID: 32847053 DOI: 10.3390/cancers12092399] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]